Key Figures Q4 2022

SEK m, unless otherwise stated

2022
Oct-Dec

2021
Oct-Dec

2022
Jan-Dec

2021
Jan-Dec

% Change

Net revenues 156 144 624 565 8.3%
Cost of goods sold -26 -20 -103 -79 -30.0%
Operating expenses -201 -188 -706 -700 -6.9%
EBIT -71 -64 -184 -214 -10.9%
EBIT margin, % -46% -45% -30% -38% -2.2%
EBITDA -53 -49 -115 -161 -8.2%
Earnings per share, before dilution, SEK -3 -2 -5 -7 -50.0%
Earnings per share, after dilution, SEK -3 -2 -5 -7 -50.0%
Cash flow from operating activities -50 -81 -157 -229 38.3%
Cash and cash equivalents 1321 504 1321 504 -73.8%


Net revenues and EBIT per segment Q4 2022

 

Net Revenues

EBIT


SEK m

2022
Oct-Dec

2021
Oct-Dec

2022
Jan-Dec

2021
Jan-Dec

2022
Oct-Dec

2021
Oct-Dec

2022
Jan-Dec

2021
Jan-Dec

ZUBSOLV® US 143 134 571 523 - - - -
US Pharma – total 143 134 571 523 77 72 308 278
Digital Therapeutics (DTx) product sales 0.0 0.3 0.4 1.1 - - - -
Digital Therapeutics (DTx) – total 0.0 0.3 0.4 1.1 -49 -64 -189 -250
Abstral® royalties 6 8 30 32 - - - -
Edluar® royalties 3 2 10 9 - - - -
ZUBSOLV® - ex US 5 - 12 - - - - -
HQ & Pipeline - total 13 10 53 41 -99 -73 -303 -243
Total 156 144 624 565 -71 -64 -184 -214


Cash flow Q4 2022


SEK m

2022
Oct-Dec

2021
Oct-Dec

2022
Jan-Dec

2021
Jan-Dec

Cash flow from operating activities -49 -81 -157 -229
Investment activities 66 -3 -235 -53
Financing activities -6 -6 -21 251
Cash flow (excl exchange rate differences) 12 -89 -413 -31
Liquid funds 1321 504 1321 504

1 Cash and cash equivalents excluding invested surplus cash of SEK 132.2 m in short-term assets, certificates of deposits and in US treasuries. As of December 31, 2022, cash and invested funds amounted to SEK 351.9 m (504.1)